Kim, Eunwoo published the artcilePharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects, Related Products of quinoxaline, the publication is International Journal of Clinical Pharmacology and Therapeutics (2021), 59(6), 478-484, database is CAplus and MEDLINE.
Varenicline is an efficacious aid for smoking cessation. In this study, the pharmacokinetics and safety were compared between film-coated tablets of varenicline tartrate (reference drug) and the newly developed orally disintegrating films of varenicline salicylate (test drug), both of them contained 1 mg of varenicline. A randomized, open-label, single-dose, two-sequence, two-period crossover study was conducted in healthy male subjects. Serial blood samples were obtained for up to 72 h in each period, with a washout period of 7 days or more. The pharmacokinetic parameters were calculated using the noncompartmental method. Safety profiles were assessed throughout the study. A total of 28 subjects completed the study. The plasma varenicline concentration-time profiles were similar for the two study drugs. The maximum plasma varenicline concentration (Cmax) was 5,768.95 ng/L (mean) and 5,780.55 ng/L for the test drug and reference drug, resp. The areas under the concentration-time curve from time 0 to the last measurable time point (AUC0 – t) were 94,086.30 h x ng/L and 89,958.55 h x ng/L for the test drug and reference drug, resp. The geometric mean ratios (90% confidence intervals) of the test drug to the reference drug for Cmax and AUC0 – t were 0.9955 (0.9488 – 1.0444) and 1.0449 (0.9848 – 1.1088), resp., which fell within the bioequivalence range of 0.8 – 1.25. There was no difference in safety between the study drugs. The pharmacokinetics and safety profiles were similar between the two study drugs. The orally disintegrating film of varenicline salicylate can be an alternative to varenicline tartrate tablets.
International Journal of Clinical Pharmacology and Therapeutics published new progress about 375815-87-5. 375815-87-5 belongs to quinoxaline, auxiliary class Neuronal Signaling,AChR,Natural product, name is 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate, and the molecular formula is C17H19N3O6, Related Products of quinoxaline.
Referemce:
https://en.wikipedia.org/wiki/Quinoxaline,
Quinoxaline | C8H6N2 | ChemSpider